50 results
6-K
IFRX
InflaRx N.V.
2 Mar 20
Current report (foreign)
4:05pm
in its development, which is the sole responsibility of BDB. Pursuant to the Co-Development Agreement, InflaRx has all global rights outside China to any
6-K
EX-5.2
IFRX
InflaRx N.V.
1 Mar 21
Current report (foreign)
12:00am
or “Blue Sky” laws of the various states. We undertake no responsibility to update or supplement this opinion in response to changes in law or future
F-3ASR
EX-5.2
IFRX
InflaRx N.V.
28 Mar 19
Automatic shelf registration (foreign)
9:09am
” laws of the various states. We undertake no responsibility to update or supplement this opinion in response to changes in law or future events or other
F-3
EX-5.2
IFRX
InflaRx N.V.
8 Jul 20
Shelf registration (foreign)
12:00am
of the securities or “Blue Sky” laws of the various states. We undertake no responsibility to update or supplement this opinion in response to changes in law
6-K
EX-99.1
IFRX
InflaRx N.V.
26 Jul 22
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:35am
related work described herein is partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility
6-K
EX-99.1
br0an07yv1y42y45mfev
29 Sep 22
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:00am
6-K
EX-99.1
nn97y2ja111 dv6
21 Dec 22
Current report (foreign)
7:45am
F-3
EX-5.2
drbvwk n82z19zq0wukt
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
nqf iq9hk9v7iqumogw
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
EX-99.1
3bggnmaov1i
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am
6-K
EX-99.1
y3fse6t1 ifc
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.1
1hvss12
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-99.1
92tyjvwpko v7o
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.4
egvg7m81uhj81evs5
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.3
q4l0gjquu0fd85vqe9
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
izgaq qfw
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
kiqn7e gwz
7 Apr 22
Current report (foreign)
4:01pm
6-K
EX-99.3
2wwngj4
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.3
opqex3h1mw ox2y9t
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.3
7c5hm32 eoy
1 Nov 23
Current report (foreign)
8:04am